Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Angiogenesis|April 1, 2011
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effectsPuja Sapra, Patricia Kraft, Fabio Pastorino, et al.
Molecular Cancer Therapeutics|July 29, 2016
Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular TomographyAnand Giddabasappa, Vijay R Gupta, Rand Norberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2010
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitorFabio Pastorino, Monica Loi, Puja Sapra, et al.
Bioconjugate Chemistry|March 29, 2008
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersHong Zhao, Belen Rubio, Puja Sapra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeysPuja Sapra, Rhona Stein, Jennifer Pickett, et al.
Neoplasia (New York, N.Y.)|November 25, 2017
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid LeukemiaCathy C Zhang, Zhengming Yan, Bernadette Pascual, et al.
Bioconjugate Chemistry|July 17, 2015
Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in MiceMauricio Leal, JoAnn Wentland, Xiaogang Han, et al.
Plos One|May 31, 2017
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugateSujiet Puthenveetil, Haiyin He, Frank Loganzo, et al.
Mabs|August 4, 2021
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft modelParul Gupta, Ziyue Karen Jiang, Bing Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint InhibitorsChanghua Ji, Marc D Roy, Jonathan Golas, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Angiogenesis|April 1, 2011
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effectsPuja Sapra, Patricia Kraft, Fabio Pastorino, et al.
Molecular Cancer Therapeutics|July 29, 2016
Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular TomographyAnand Giddabasappa, Vijay R Gupta, Rand Norberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2010
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitorFabio Pastorino, Monica Loi, Puja Sapra, et al.
Bioconjugate Chemistry|March 29, 2008
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersHong Zhao, Belen Rubio, Puja Sapra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeysPuja Sapra, Rhona Stein, Jennifer Pickett, et al.
Neoplasia (New York, N.Y.)|November 25, 2017
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid LeukemiaCathy C Zhang, Zhengming Yan, Bernadette Pascual, et al.
Bioconjugate Chemistry|July 17, 2015
Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in MiceMauricio Leal, JoAnn Wentland, Xiaogang Han, et al.
Plos One|May 31, 2017
Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugateSujiet Puthenveetil, Haiyin He, Frank Loganzo, et al.
Mabs|August 4, 2021
Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft modelParul Gupta, Ziyue Karen Jiang, Bing Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint InhibitorsChanghua Ji, Marc D Roy, Jonathan Golas, et al.
Pageof 6